Novartis AG has appointed Joerg Reinhardt, currently head of vaccines and diagnostics, to the new post of chief operating officer, effective 1 December 2008.
He will report to Daniel Vasella, the company’s chairman and chief executive officer.
Replacing Dr Reinhardt as head of vaccines and diagnostics is Andrin Oswald, currently CEO of the Swiss company, Speedel Holding AG. Novartis acquired Speedel in September.
Prior to overseeing vaccines and diagnostics, Dr Reinhardt was global head of development in Novartis’s pharmaceutical division overseeing clinical, pharmaceutical, chemical and biotechnological product development, drug safety and regulatory affairs. He holds a Ph.D. in pharmaceutical sciences from the University of Saarbrücken in Germany.
Copyright 2008 Evernow Publishing Ltd